Browse by author
Lookup NU author(s): Dr Michael Grayling,
Professor James Wason
This is the authors' accepted manuscript of an article that has been published in its final definitive form by Taylor and Francis Inc., 2019.
For re-use rights please refer to the publisher's terms and conditions.
© 2019, © 2019 American Statistical Association. Bioequivalence (BE) studies are most often conducted as crossover trials, and therefore establishing their required sample size necessitates specification of the within-person variance. Given that this specification is often difficult in practice, there has been great interest in recent years in the use of adaptive designs for BE trials. However, while numerous methods for this have now been presented, their focus has been solely on two-treatment BE studies. In some instances, it will be desired to incorporate more than a single test and reference formulation into a BE trial. It would therefore be useful to establish methodology for the design of adaptive multi-treatment BE trials, to acquire the benefits in the two-treatment setting in this more complex situation. Here, we achieve this for three-treatment studies by extending previously proposed designs for two-treatment trials. First, we discuss the additional design considerations that arise when multiple comparisons are made. Next, an extensive simulation study is employed to compare the performance of the proposed procedures. With this, we demonstrate that two-stage designs with desirable statistical operating characteristics can be readily identified for three-treatment BE trials. Supplementary materials for this article are available online.
Author(s): Grayling MJ, Mander AP, Wason JMS
Publication type: Article
Publication status: Published
Journal: Statistics in Biopharmaceutical Research
Online publication date: 13/08/2019
Acceptance date: 05/08/2019
Date deposited: 29/10/2019
ISSN (electronic): 1946-6315
Publisher: Taylor and Francis Inc.
Altmetrics provided by Altmetric